-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In March 2022, more than 30 innovative drug companies in China have completed financing
Looking at the subdivision track , including Yilian Bio, which focuses on ADC ; companies focusing on gene therapy include: Huayi Lejian, Jinweike Bio, Biojing Bio, Qi Heshengke, Zhongyin Technology, Xingmu Biology, and Piwang Pharmaceutical, which focuses on the field of small nucleic acids ; Blue Horse Medical, Kati Medical, Kaidi Medical, Yuesai Bio, Xin Chuan Bio, and Aikali Yuan, which focus on cell therapy ; Genovax, which focuses on vaccine research and development , Convinced Biology; Orui Pharmaceutical, which focuses on the research and development of targeted protein degraders, etc.
Looking at the ADC field , the field of gene therapy, the field of small nucleic acid, the field of cell therapy vaccines , targeted protein degraders
In terms of the amount of financing , different rounds indirectly represent the development stage of the company.
Look at Bowang Pharmaceutical in terms of financing amount
-Summary of investment and financing in the field of innovativedrugs-
Summary of investment and financing in the field of innovative drugs
The field of gene therapy
The field of gene therapy1.
1.
2.
2.
Zhongyin Technology's R&D pipeline
Zhongyin Technology's R&D pipeline
3.
3.
2.
2.
Shipwang Pharmaceuticals
Shipwang Pharma is committed to developing a new generation of RNAi drugs
The field of cell therapy
The field of cell therapy1.
1.
2.
2.
3.
Ai Kelly Yuan
Ai Kelly Yuan
Aikaliyuan is a new generation of general-purpose off-the-shelf cell therapy drug developers.
At present, it has formed a profound technical accumulation in iPSC reprogramming, gene editing, stem cell differentiation, etc.
, and has achieved a series of original breakthroughs in the iPSC field.
.
Up to now, in less than a year, Aika Biotech has successfully completed three rounds of financing, with a total of more than 300 million yuan, which has won the focus and high recognition of the capital market
.
The field of vaccines
The field of vaccinesBelieve in biology
Believe in biology Established in November 2019, INNORNA is one of the few companies in the world with core mRNA delivery technology
.
It is at the international leading level in research and development methods, mRNA design, synthesis and modification, and delivery routes
.
Its unique intellectual property LNP delivery platform can meet the delivery needs of different types of mRNA drugs
.
At present, the company has established international advanced R&D laboratories in Shenzhen, Nanjing and Hong Kong, and has an excellent scientific research and management team
.
5.
Targeted protein degraders
Targeted protein degraders
Orui Pharmaceutical
Orui Pharmaceutical Nanjing Orui is a biopharmaceutical enterprise with tissue-specific E3 ligase (the core element of PROTAC technology) and an efficient in vitro screening platform for coronavirus drugs with independent intellectual property rights
.
The company applies PROTAC technology to target "unable to be druggable" tumor targets, focusing on unmet clinical needs, and has laid out a number of new drug pipelines
.
It is reported that drug candidates such as AR-PROTAC, the glioma project, and the viral entry inhibitor of the spike protein are being advanced
.
